Get the Stockscreener App
7.525
2.31%
-0.185
Kura Oncology Inc stock is traded at $7.525, with a volume of 137.95K.
It is down -2.31% in the last 24 hours and down -9.03% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$7.71
Open:
$7.7
24h Volume:
137.95K
Relative Volume:
0.09
Market Cap:
$626.66M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.4677
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-2.18%
1M Performance:
-9.03%
6M Performance:
-63.93%
1Y Performance:
-67.01%
1-Day Range:
$7.53
$7.93
1-Week Range:
$6.79
$7.93
52-Week Range:
$6.79
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.53 | 626.66M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.29 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily
Kura Oncology Inc (KURA) Q4 2024 Earnings: EPS of -$0.22 Beats E - GuruFocus.com
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies By Investing.com - Investing.com UK
Kura Oncology stock hits 52-week low at $6.98 amid challenges - Investing.com Australia
Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA) - Defense World
UBS Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Metrics That Matter About Kura Oncology Inc (NASDAQ: KURA) - Stocks Register
Kura Oncology's Latest Strategic Move: 190K Share Options Package Draws Top Talent - StockTitan
Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology price target lowered to $14 from $27 at UBS - TipRanks
Cantor Fitzgerald Comments on Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com - Defense World
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating -March 06, 2025 at 09:52 am EST - Marketscreener.com
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future - Investing.com India
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62% - Simply Wall St
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity - Seeking Alpha
Brokers Issue Forecasts for Kura Oncology FY2026 Earnings - Defense World
FY2025 EPS Estimate for Kura Oncology Reduced by Analyst - Defense World
HC Wainwright Predicts Kura Oncology Q2 Earnings - Defense World
Wedbush Estimates Kura Oncology’s Q1 Earnings (NASDAQ:KURA) - Defense World
Kura Oncology’s (KURA) Outperform Rating Reiterated at Wedbush - Defense World
HC Wainwright Weighs in on Kura Oncology Q1 Earnings - Armenian Reporter
Brokers Offer Predictions for Kura Oncology Q1 Earnings - Armenian Reporter
Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns - TipRanks
Research Analysts Set Expectations for Kura Oncology Q1 Earnings - MarketBeat
Equities Analysts Issue Forecasts for Kura Oncology Q1 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com - Defense World
Kura Oncology (NASDAQ:KURA) Upgraded at StockNews.com - MarketBeat
Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush - MarketBeat
Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago - Yahoo Finance
Kura Oncology’s Positive Earnings Call Highlights Progress and Prospects - TipRanks
Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Beats Estimates By $0.43 EPS - MarketBeat
Investor Network: Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Call Transcript - Insider Monkey
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Kura Oncology’s Promising Path to FDA Approval: Analyst Recommends ‘Buy’ Following Positive Phase II Results and Strategic Advancements - TipRanks
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth - Yahoo Finance
Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Kura Oncology’s Strategic Advancements and Financial Health Drive Buy Rating - TipRanks
Kura Oncology: Q4 Earnings Snapshot - The Washington Post
Kura Oncology Advances Cancer Drug Development - TipRanks
Kura Oncology Inc earnings beat by $0.35, revenue topped estimates - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology: Q4 Earnings Snapshot -February 26, 2025 at 04:42 pm EST - Marketscreener.com
Can Kura Oncology's Breakthrough AML Treatment Reshape the Blood Cancer Market? - StockTitan
Kura Oncology to Participate in Three Upcoming Investor Conferences - The Manila Times
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer |
Jan 28 '25 |
Sale |
7.87 |
4,963 |
39,068 |
88,253 |
| Bair Teresa Brophy | Chief Legal Officer |
Jan 28 '25 |
Sale |
7.87 |
7,281 |
57,315 |
107,948 |
| FORD KATHLEEN | Chief Operating Officer |
Jan 28 '25 |
Sale |
7.87 |
1,817 |
14,303 |
21,367 |
| Burrows Francis | Chief Scientific Officer |
Jan 28 '25 |
Sale |
7.87 |
2,166 |
17,051 |
20,705 |
| Powl Brian T. | Chief Commercial Officer |
Jan 28 '25 |
Sale |
7.87 |
1,583 |
12,461 |
59,667 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):